Rechargeable bladder device could save money, study hopes

NCT ID NCT07173517

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study will compare the costs of two types of sacral neuromodulation devices—rechargeable and non-rechargeable—for treating neurogenic lower urinary tract dysfunction. Researchers will track expenses in 268 patients who have not responded to standard treatments. The goal is to see if the newer rechargeable device is more budget-friendly over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
sacral neuromodulation device (rechargeable vs non-rechargeable)
What this could lead to
If rechargeable devices prove cheaper, hospitals may switch to them, potentially lowering long-term costs for patients with bladder control problems.
What could go wrong
This is an observational cost study, not a treatment trial. It won't test if the devices work better, only their cost impact. Results may not apply to all patients or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROGENIC LOWER URINARY TRACT DYSFUNCTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Qilu Hospital

    Jinan, Shandong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.